Search

Your search keyword '"Piperno-Neumann S"' showing total 545 results
Start Over Author "Piperno-Neumann S"
545 results on '"Piperno-Neumann S"'

2. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial

Author

Audinot, B., Drubay, D., Gaspar, N., Mohr, A., Cordero, C., Marec-Bérard, P., Lervat, C., Piperno-Neumann, S., Jimenez, M., Mansuy, L., Castex, M.-P., Revon-Riviere, G., Marie-Cardine, A., Berger, C., Piguet, C., Massau, K., Job, B., Moquin-Beaudry, G., Le Deley, M.-C., Tabone, M.-D., Berlanga, P., Brugières, L., Crompton, B.D., Marchais, A., and Abbou, S.

Published
2024
Full Text
View/download PDF

3. Improved nationwide survival of sarcoma patients with a network of reference centers

Author

Blay, J.Y., Penel, N., Valentin, T., Anract, P., Duffaud, F., Dufresne, A., Verret, B., Cordoba, A., Italiano, A., Brahmi, M., Henon, C., Amouyel, T., Ray-Coquard, I., Ferron, G., Boudou-Rouquette, P., Tlemsani, C., Salas, S., Rochwerger, R., Faron, M., Bompas, E., Ducassou, A., Gangloff, D., Gouin, F., Firmin, N., Piperno-Neumann, S., Rios, M., Ropars, M., Kurtz, J.E., Le Nail, L.R., Bertucci, F., Carrere, S., Llacer, C., Watson, S., Bonvalot, S., Leroux, A., Perrin, C., Gantzer, J., Pracht, M., Narciso, B., Monneur, A., Lebbe, C., Hervieu, A., Saada-Bouzid, E., Dubray-Longeras, P., Fiorenza, F., Chaigneau, L., Nevieres, Z.-M., Soibinet, P., Bouché, O., Guillemet, C., Spano, J.P., Ruzic, J.C., Isambert, N., Vaz, G., Meeus, P., Karanian, M., Ngo, C., Coindre, J.M., De Pinieux, G., Le Loarer, F., Ducimetiere, F., Chemin, C., Morelle, M., Toulmonde, M., and Le Cesne, A.

Published
2024
Full Text
View/download PDF

6. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years

Author

Blay, JY, Piperno-Neumann, S., Watson, S., Dufresne, A., Valentin, T., Duffaud, F., Toulmonde, M., Italiano, A., Bertucci, F., Tlemsani, C., Firmin, N., Bompas, E., Perrin, C., Ropars, M., Saada-Bouzid, E., Dubray-Longeras, P., Hervieu, A., Lebbe, C., Gantzer, J., Chaigneau, L., Fiorenza, F., Rios, M., Isambert, N., Soibinet, P., Boudou-Roquette, P., Verret, B., Ferron, G., Ryckewaert, T., Lebellec, L., Brahmi, M., Gouin, F., Meeus, P., Vaz, G., Le Loarer, F., Karanian, M., De Pinieux, G., Ducimetiere, F., Chemin, C., Morelle, M., Le Cesne, A., and Penel, N.

Published
2023
Full Text
View/download PDF

10. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

Author

Moreau-Bachelard, C., Campion, L., Toulmonde, M., Le Cesne, A., Brahmi, M., Italiano, A., Mir, O., Piperno-Neumann, S., Laurence, V., Firmin, N., Penel, N., Duffaud, F., Chevreau, C., Bertucci, F., Narciso, B., Dubray-Longeras, P., Delcambre, C., Saada-Bouzid, E., Boudou-Rouquette, P., Soulie, P., Perrin, C., Blay, J.Y., and Bompas, E.

Published
2022
Full Text
View/download PDF

11. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Author

Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., Isambert, N., Chevreau, C., Bompas, E., Bertucci, F., Chaigneau, L., Piperno-Neumann, S., Salas, S., Rios, M., Guillemet, C., Bay, J.-O., Ray-Coquard, I., Haddag, L., Bonastre, J., Kapso, R., Fraslin, A., Bouvet, N., Mir, O., and Foulon, S.

Published
2021
Full Text
View/download PDF

12. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

Author

Pautier, P., Floquet, A., Chevreau, C., Penel, N., Guillemet, C., Delcambre, C., Cupissol, D., Selle, F., Isambert, N., Piperno-Neumann, S., Saada-Bouzid, E., Bertucci, F., Bompas, E., Alexandre, J., Collard, O., Lebrun-Ly, V., Soulier, P., Toulmonde, M., Le Cesne, A., Lacas, B., and Duffaud, F.

Published
2021
Full Text
View/download PDF

13. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

Author

Stacchiotti, S., Miah, A.B., Frezza, A.M., Messiou, C., Morosi, C., Caraceni, A., Antonescu, C.R., Bajpai, J., Baldini, E., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Callegaro, D., De Alava, E., Deoras-Sutliff, M., Dufresne, A., Eriksson, M., Errani, C., Fedenko, A., Ferraresi, V., Ferrari, A., Fletcher, C.D.M., Garcia del Muro, X., Gelderblom, H., Gladdy, R.A., Gouin, F., Grignani, G., Gutkovich, J., Haas, R., Hindi, N., Hohenberger, P., Huang, P., Joensuu, H., Jones, R.L., Jungels, C., Kasper, B., Kawai, A., Le Cesne, A., Le Grange, F., Leithner, A., Leonard, H., Lopez Pousa, A., Martin Broto, J., Merimsky, O., Merriam, P., Miceli, R., Mir, O., Molinari, M., Montemurro, M., Oldani, G., Palmerini, E., Pantaleo, M.A., Patel, S., Piperno-Neumann, S., Raut, C.P., Ravi, V., Razak, A.R.A., Reichardt, P., Rubin, B.P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sapisochin, G., Sbaraglia, M., Scheipl, S., Schöffski, P., Strauss, D., Strauss, S.J., Sundby Hall, K., Tap, W.D., Trama, A., Tweddle, A., van der Graaf, W.T.A., Van De Sande, M.A.J., Van Houdt, W., van Oortmerssen, G., Wagner, A.J., Wartenberg, M., Wood, J., Zaffaroni, N., Zimmermann, C., Casali, P.G., Dei Tos, A.P., and Gronchi, A.

Published
2021
Full Text
View/download PDF

14. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Blay, J.Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dufresne, A., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S.J., Hall, K Sundby, Trama, A., Unk, M., van de Sande, M.A.J., van der Graaf, W.T.A., van Houdt, W.J., Frebourg, T., Gronchi, A., and Stacchiotti, S.

Published
2021
Full Text
View/download PDF

15. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Author

Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CTS151: Bioquímica médica., Piulats, J. M., Watkins, C., Costa García, M., del Carpio, L., Piperno-Neumann, S., Rutkowski, P., Cruz Merino, Luis de la, Nathan, P., Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CTS151: Bioquímica médica., Piulats, J. M., Watkins, C., Costa García, M., del Carpio, L., Piperno-Neumann, S., Rutkowski, P., Cruz Merino, Luis de la, and Nathan, P.

Abstract

Background: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator’s choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N ¼ 378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively. In the single-arm GEM1402 (N ¼ 52), the 1-year OS rate for nivolumab plus ipilimumab (NþI) in mUM was 52%. Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to NþI (GEM1402) in untreated mUM using propensity scoring methods. Patients and methods: Analyses were adjusted using propensity score-based inverse probability of treatment weighting (IPTW), balancing age, sex, baseline lactate dehydrogenase (LDH), baseline alkaline phosphatase, disease location, Eastern Cooperative Oncology Group status, and time from primary diagnosis to metastasis. OS was assessed using IPT-weighted KaplaneMeier and Cox proportional hazard models. Sensitivity analyses using alternative missing data and weights methods were conducted. Results: The primary IPTW analysis included 240 of 252 patients randomized to tebentafusp from IMCgp100-202 and 45 of 52 NþI-treated patients from GEM-1402. Key baseline covariates, including LDH, were generally well balanced before weighting. The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for NþI. Sensitivity analyses showed consistent superior OS for tebentafusp with all IPTW HRs 0.61. IPTW analysis of pembrolizumab versus NþI showed no significant difference in OS (HR 0.72; 95% CI 0.50-1.06). Conclusions: Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM. Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with NþI. These data further support tebentafusp

Published
2024

17. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial

Author

Audinot, B., primary, Drubay, D., additional, Gaspar, N., additional, Mohr, A., additional, Cordero, C., additional, Marec-Bérard, P., additional, Lervat, C., additional, Piperno-Neumann, S., additional, Jimenez, M., additional, Mansuy, L., additional, Castex, M.-P., additional, Revon-Riviere, G., additional, Marie-Cardine, A., additional, Berger, C., additional, Piguet, C., additional, Massau, K., additional, Job, B., additional, Moquin-Beaudry, G., additional, Le Deley, M.-C., additional, Tabone, M.-D., additional, Berlanga, P., additional, Brugières, L., additional, Crompton, B.D., additional, Marchais, A., additional, and Abbou, S., additional

Published
2023
Full Text
View/download PDF

18. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

Author

Khoja, L., Atenafu, E.G., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., Keilholz, U., Zimmer, L., Patel, S.P., Piperno-Neumann, S., Piulats, J., Kivelä, T.T., Pfoehler, C., Bhatia, S., Huppert, P., Van Iersel, L.B.J., De Vries, I.J.M., Penel, N., Vogl, T., Cheng, T., Fiorentini, G., Mouriaux, F., Tarhini, A., Patel, P.M., Carvajal, R., and Joshua, A.M.

Published
2019
Full Text
View/download PDF

19. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Bielack, S., Abecassis, N., Aro, H.T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J V M G, Brennan, B., Brodowicz, T., Broto, J.M., Brugières, L., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dileo, P., Dhooge, C., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gaspar, N., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hassan, B., Hecker-Nolting, S., Hohenberger, P., Issels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kager, L., Kasper, B., Kopeckova, K., Krákorová, D.A., Ladenstein, R., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Morland, B., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkowski, P., Safwat, A.A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Strauss, S.J., Sundby Hall, K., Unk, M., Van Coevorden, F., van der Graaf, W.T.A., Whelan, J., Wardelmann, E., Zaikova, O., and Blay, J.Y.

Published
2018
Full Text
View/download PDF

20. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J V M G, Brodowicz, T., Broto, J.M., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hannu, A., Hassan, B., Hohenberger, P., Issels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kasper, B., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkowski, P., Safwat, A.A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., Van der Graaf, W., Whelan, J., Wardelmann, E., Zaikova, O., and Blay, J.Y.

Published
2018
Full Text
View/download PDF

21. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Brodowicz, T., Broto, J.M., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hannu, A., Hassan, B., Hohenberger, P., Issels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kasper, B., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkowski, P., Safwat, A.A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., Van der Graaf, W., Whelan, J., Wardelmann, E., Zaikova, O., and Blay, J.Y.

Published
2018
Full Text
View/download PDF

22. Improved survival using specialized multidisciplinary board in sarcoma patients

Author

Blay, J.-Y., Soibinet, P., Penel, N., Bompas, E., Duffaud, F., Stoeckle, E., Mir, O., Adam, J., Chevreau, C., Bonvalot, S., Rios, M., Kerbrat, P., Cupissol, D., Anract, P., Gouin, F., Kurtz, J. -E., Lebbe, C., Isambert, N., Bertucci, F., Toumonde, M., Thyss, A., Piperno-Neumann, S., Dubray-Longeras, P., Meeus, P., Ducimetière, F., Giraud, A., Coindre, J. -M., Ray-Coquard, I., Italiano, A., and Le Cesne, A.

Published
2017
Full Text
View/download PDF

24. Gastrointestinal stromal tumours

Author

Casali, P.G., Blay, J.Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Buonadonna, A., Alava, E. de, Tos, A.P. dei, Muro, X.G. del, Dufresne, A., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Grange, F. le, Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Strauss, S.J., Hall, K.S., Trama, A., Unk, M., Sande, M.A.J. van de, Graaf, W.T.A. van der, Houdt, W.J. van, Frebourg, T., Gronchi, A., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Buonadonna A., De Alava E., Dei Tos A.P., Del Muro X.G., Dufresne A., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Strauss S.J., Hall K.S., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Gronchi A., Stacchiotti S., Medical Oncology, ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), and Man, Biomaterials and Microbes (MBM)

Subjects
GIST, clinical practice guidelines, gastrointestinal stromal tumour, surgery, tyrosine kinase inhibitor, Oncology, Medizin, Hematology, clinical practice guideline
Abstract

Gastrointestinal stromal tumours (GISTs) are malignant mesenchymal tumours with a variable clinical behaviour, marked by differentiation towards the interstitial cells of Cajal.1 GISTs belong to the family of soft tissue sarcomas (STSs) but are treated separately due to their peculiar histogenesis, clinical behaviour and specific therapy. This European Society for Medical Oncology (ESMO)–European Reference Network for Rare Adult Solid Cancers (EURACAN)–European Reference Network for Genetic Tumour Risk Syndromes (GENTURIS) Clinical Practice Guideline (CPG) will cover GISTs while other STSs are covered in the ESMO–EURACAN–European Reference Network for Paediatric Oncology (ERN PaedCan)–GENTURIS STS CPG.

Published
2022

26. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

Strauss, S.J., Frezza, A.M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., Alava, E. de, Tos, A.P. dei, Muro, X.G. del, Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Grange, F. le, Legius, E., Leithner, A., Pousa, A.L., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Hall, K.S., Trama, A., Unk, M., Sande, M.A.J. van de, Graaf, W.T.A. van der, Houdt, W.J. van, Frebourg, T., Ladenstein, R., Casali, P.G., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, ERN PaedCan, European Society for Medical Oncology, Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Alava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), and Man, Biomaterials and Microbes (MBM)

Subjects
medicine.medical_specialty, diagnosis, Medizin, bone sarcoma, Bone Neoplasm, Bone Sarcoma, Follow-Up Studie, 03 medical and health sciences, 0302 clinical medicine, follow-up, medicine, 030304 developmental biology, Osteosarcoma, 0303 health sciences, treatment, business.industry, Sarcoma, Hematology, Guideline, clinical practice guideline, management, 3. Good health, Clinical Practice, diagnosi, Oncology, Diagnosis treatment, 030220 oncology & carcinogenesis, Radiology, business, Human
Abstract

A. Kawai43, K. Kopeckova44, D. A. Krakorova45, A. Le Cesne46, F. Le Grange1, E. Legius47, A. Leithner48, A. Lopez Pousa49, J. Martin-Broto36, O. Merimsky50, C. Messiou51, A. B. Miah52, O. Mir53, M. Montemurro54, B. Morland55, C. Morosi56, E. Palmerini57, M. A. Pantaleo58, R. Piana59, S. Piperno-Neumann60, P. Reichardt61, P. Rutkowski62, A. A. Safwat63, C. Sangalli64, M. Sbaraglia19, S. Scheipl48, P. Schoffski65, S. Sleijfer66, D. Strauss67, K. Sundby Hall13, A. Trama68, M. Unk69, M. A. J. van de Sande70, W. T. A. van der Graaf66,71, W. J. van Houdt72, T. Frebourg73x, R. Ladenstein41z, P. G. Casali2,74z &

Published
2021

27. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age

Author

Bouttefroy, S., primary, Penel, N., additional, Orbach, D., additional, Minard-Colin, V., additional, Le Cesne, A., additional, Blay, JY, additional, Marec-Berard, P., additional, Verité, C., additional, Laurence, V., additional, Piperno-Neumann, S., additional, Defachelles, AS., additional, Bompas, E., additional, Chevreau, C., additional, Duffaud, F., additional, Salas, S., additional, Morelle, M., additional, Jean-Denis, M., additional, Italiano, A., additional, Bonvalot, S., additional, and Corradini, N., additional

Published
2023
Full Text
View/download PDF

29. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Author

Benson, C., Ray-Coquard, I., Sleijfer, S., Litière, S., Blay, J.-Y., Le Cesne, A., Papai, Z., Judson, I., Schöffski, P., Chawla, S., Gil, T., Piperno-Neumann, S., Marréaud, S., Dewji, M.R., and van der Graaf, W.T.A.

Published
2016
Full Text
View/download PDF

31. 1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network

Author

Blay, J-Y., primary, Italiano, A., additional, Penel, N., additional, Bompas, E., additional, Duffaud, F., additional, Chevreau, C.M., additional, Anract, P., additional, Perrin, C., additional, Firmin, N., additional, Toulmonde, M., additional, Piperno-Neumann, S., additional, Watson, S., additional, Rios, M., additional, Kurtz, J.E., additional, Bertucci, F., additional, Le Loarer, F., additional, Chemin, C., additional, Morelle, M., additional, Gouin, F., additional, and Le Cesne, A., additional

Published
2022
Full Text
View/download PDF

32. 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma

Author

Piulats Rodriguez, J.M., primary, Piperno-Neumann, S., additional, Rutkowski, P., additional, Nathan, P., additional, Hassel, J.C., additional, Espinosa, E., additional, de la Cruz Merino, L., additional, Ochsenreither, S., additional, Shoushtari, A.N., additional, Orloff, M., additional, Salama, A.K.S., additional, Watkins, C., additional, Goodall, H., additional, and Baurain, J-F., additional

Published
2022
Full Text
View/download PDF

34. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group

Author

Toulmonde, M., Bonvalot, S., Méeus, P., Stoeckle, E., Riou, O., Isambert, N., Bompas, E., Jafari, M., Delcambre-Lair, C., Saada, E., Le Cesne, A., Le Péchoux, C., Blay, J.Y., Piperno-Neumann, S., Chevreau, C., Bay, J.O., Brouste, V., Terrier, P., Ranchère-Vince, D., Neuville, A., and Italiano, A.

Published
2014
Full Text
View/download PDF

36. Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group

Author

Toulmonde, M., Bonvalot, S., Ray-Coquard, I., Stoeckle, E., Riou, O., Isambert, N., Bompas, E., Penel, N., Delcambre-Lair, C., Saada, E., Lecesne, A., Le Péchoux, C., Blay, J.Y., Piperno-Neumann, S., Chevreau, C., Bay, J.O., Brouste, V., Terrier, P., Ranchère-Vince, D., Neuville, A., and Italiano, A.

Published
2014
Full Text
View/download PDF

37. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours long-term follow-up of nilotinib in TGCT

Author

Spierenburg, G., Grimison, P., Chevreau, C., Stacchiotti, S., Piperno-Neumann, S., Cesne, A. le, Ferraresi, V., Italiano, A., Duffaud, F., Penel, N., Metzger, S., Chabaud, S., Heijden, L. van der, Perol, D., Sande, M.A.J. van de, Blay, J.Y., and Gelderblom, H.

Subjects
PVNS, TGCT, CSF1, Tyrosine kinase inhibitor, Nilotinib, CSF1R inhibitor
Abstract

Background: Diffuse-type tenosynovial giant cell tumour (D-TGCT) is a nonmalignant but locally aggressive tumour driven by overexpression of colony-stimulating factor-1 (CSF1). CSF1R inhibitors are potential therapeutic strategies for patients not amenable to surgery. We report here the long-term outcome of nilotinib in patients with advanced D-TGCT treated within a phase II prospective international study (ClinicalTrials.gov: NCT01261429). Methods: Patients were enrolled between December 2010-September 2012 at 11 cancer centres. Eligible patients had histologically confirmed D-TGCT, not amenable to surgery. Patients received nilotinib until evidence of progression, toxicity or a maximum of one year. Long-term data were retrospectively collected after the completion of the phase II trial. Patients with nilotinib treatment >= 12 weeks and follow-up >= 12 months were included for long-term analysis. Results: Forty-eight of 56 enrolled patients were included. Median treatment duration was 11 months; 31 (65%) patients completed the treatment protocol. After 102 months of follow-up (median; range 12-129), 25 patients (52%) had progression. The median progression-free survival (PFS) was 77 months. The five-year PFS rate was 53%. Fifteen patients (n=15/46; 33%) experienced clinical worsening after 11 months (median). Twenty-seven patients (58%) received additional treatment, after which eleven patients (n = 11/27; 41%) had a second relapse. Nine patients required a subsequent treatment, primarily other CSF1R inhibitors (n = 6/9; 67%). No unfavourable long-term effects were observed. Conclusion: This long-term analysis of nilotinib for advanced D-TGCT showed that about half of the patients had progression and underwent additional treatment after 8.5 years follow-up. Contrarily, several patients had ongoing disease control after limited treatment duration, demonstrating the mixed effect of nilotinib.

Published
2022

38. Soft tissue and visceral sarcomas

Author

Gronchi, A., Miah, A.B., DeiTos, A.P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., DeAlava, E., Muro, X.G. del, Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, LeGrange, F., Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Strauss, S., SundbyHall, K., Trama, A., Unk, M., VandeSande, M.A.J., VanderGraaf, W.T.A., Houdt, W.J. van, Frebourg, T., Casali, P.G., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), Man, Biomaterials and Microbes (MBM), Gronchi A., Miah A.B., Dei Tos A.P., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., De Alava E., Del Muro X.G., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Strauss S., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Casali P.G., and Stacchiotti S.

Subjects
sarcoma, uterine sarcoma, treatment, diagnosis, desmoid, Medizin, Sarcoma, Soft Tissue Neoplasms, Hematology, Clinical Practice Guideline, Soft tissue sarcomas, retroperitoneal sarcoma, Retroperitoneal Sarcoma, soft tissue sarcomas, Follow-Up Studie, Desmoid, Uterine Sarcoma, follow-up, management, Oncology, soft tissue sarcoma, Human
Abstract

ispartof: ANNALS OF ONCOLOGY vol:32 issue:11 pages:1348-1365 ispartof: location:England status: published

Published
2021

39. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, Paolo G., Blay, Jean-Yves, Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brodowicz, T., Buonadonna, A., Álava, Enrique de, Tos, A. P. dei, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Haas, R. L., Hassan, A. B., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, A, Le Grange, F, Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S. J., Sundby-Hall, Kirsten, Trama, A., Unk, M., Sande, M. A. J. van de, Graaf, W.T.A. van der, Houdt, W. J. van, Frebourg, T., Gronchi, Alesandro, Stacchiotti, Silvia, ESMO Guidelines Committee, EURACAN, GENTURIS, Casali, Paolo G., Blay, Jean-Yves, Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brodowicz, T., Buonadonna, A., Álava, Enrique de, Tos, A. P. dei, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Haas, R. L., Hassan, A. B., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, A, Le Grange, F, Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S. J., Sundby-Hall, Kirsten, Trama, A., Unk, M., Sande, M. A. J. van de, Graaf, W.T.A. van der, Houdt, W. J. van, Frebourg, T., Gronchi, Alesandro, Stacchiotti, Silvia, ESMO Guidelines Committee, EURACAN, and GENTURIS

Abstract

Gastrointestinal stromal tumours (GISTs) are malignant mesenchymal tumours with a variable clinical behaviour, marked by differentiation towards the interstitial cells of Cajal.1 GISTs belong to the family of soft tissue sarcomas (STSs) but are treated separately due to their peculiar histogenesis, clinical behaviour and specific therapy. This European Society for Medical Oncology (ESMO)–European Reference Network for Rare Adult Solid Cancers (EURACAN)–European Reference Network for Genetic Tumour Risk Syndromes (GENTURIS) Clinical Practice Guideline (CPG) will cover GISTs while other STSs are covered in the ESMO–EURACAN–European Reference Network for Paediatric Oncology (ERN PaedCan)–GENTURIS STS CPG.

Published
2022

41. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., primary, Blay, J.Y., additional, Abecassis, N., additional, Bajpai, J., additional, Bauer, S., additional, Biagini, R., additional, Bielack, S., additional, Bonvalot, S., additional, Boukovinas, I., additional, Bovee, J.V.M.G., additional, Boye, K., additional, Brodowicz, T., additional, Buonadonna, A., additional, De Álava, E., additional, Dei Tos, A.P., additional, Del Muro, X.G., additional, Dufresne, A., additional, Eriksson, M., additional, Fedenko, A., additional, Ferraresi, V., additional, Ferrari, A., additional, Frezza, A.M., additional, Gasperoni, S., additional, Gelderblom, H., additional, Gouin, F., additional, Grignani, G., additional, Haas, R., additional, Hassan, A.B., additional, Hindi, N., additional, Hohenberger, P., additional, Joensuu, H., additional, Jones, R.L., additional, Jungels, C., additional, Jutte, P., additional, Kasper, B., additional, Kawai, A., additional, Kopeckova, K., additional, Krákorová, D.A., additional, Le Cesne, A., additional, Le Grange, F., additional, Legius, E., additional, Leithner, A., additional, Lopez-Pousa, A., additional, Martin-Broto, J., additional, Merimsky, O., additional, Messiou, C., additional, Miah, A.B., additional, Mir, O., additional, Montemurro, M., additional, Morosi, C., additional, Palmerini, E., additional, Pantaleo, M.A., additional, Piana, R., additional, Piperno-Neumann, S., additional, Reichardt, P., additional, Rutkowski, P., additional, Safwat, A.A., additional, Sangalli, C., additional, Sbaraglia, M., additional, Scheipl, S., additional, Schöffski, P., additional, Sleijfer, S., additional, Strauss, D., additional, Strauss, S.J., additional, Hall, K Sundby, additional, Trama, A., additional, Unk, M., additional, van de Sande, M.A.J., additional, van der Graaf, W.T.A., additional, van Houdt, W.J., additional, Frebourg, T., additional, Gronchi, A., additional, and Stacchiotti, S., additional

Published
2022
Full Text
View/download PDF

44. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states

Author

Blay, J-Y, Casali, P, Bouvier, C, Dehais, C, Galloway, I, Gietema, J, Halámková, J, Hindi, N, Idbaih, A, Kinloch, E, Klümpen, H-J, Kolarova, T, Kopeckova, K, Lovey, J, Magalhaes, M, Oselin, K, Piperno-Neumann, S, Ravnsbaek, A, Rogasik, M, Safwat, A, Scheipl, S, Seckl, M, Taylor, J, Temnyk, M, Trama, A, Urbonas, M, Wartenberg, M, Weinman, A, EURACAN Network, Oncology, CCA - Cancer Treatment and Quality of Life, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], University of Milan, Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], Royal Free Hospital [London, UK], Service de neurologie 2 [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Groningen [Groningen] (UMCG), Masaryk Memorial Cancer Institute (RECAMO), Hospital Universitario Virgen del Rocío [Sevilla], University of Amsterdam [Amsterdam] (UvA), University Hospital Motol [Prague], National Institute of Oncology [Budapest, Hungary], Centro Hospitalar do Porto, North Estonia Medical Center, Institut Curie [Paris], Aarhus University Hospital, Karl-Franzens-Universität [Graz, Autriche], Charing Cross Hospital & Imperial College, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Kaunas University of Technology (KTU), EURORDIS-Rare Diseases Europe (Bureau de Paris), EURORDIS - Plateforme Maladies Rares [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and University of Graz

Subjects
Cancer Research, medicine.medical_specialty, Statement (logic), MEDLINE, [SDV.CAN]Life Sciences [q-bio]/Cancer, News, GUIDELINES, DIAGNOSIS, 03 medical and health sciences, 0302 clinical medicine, EURACAN Network, Health care, medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, business.industry, Member states, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Family medicine, SURVIVAL, Position paper, SARCOMA PATIENTS, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, BURDEN
Abstract

International audience

Published
2021

45. 1522MO Hormonal contraception and pregnancy and risk of progression or relapse in desmoid-type fibromatosis (DF)

Author

Debaudringhien, M., primary, Blay, J-Y., additional, Bimbai, A.M., additional, Bonvalot, S., additional, Italiano, A., additional, Rousset-Jablonski, C., additional, Corradini, N., additional, Piperno-Neumann, S., additional, Chevreau, C.M., additional, Kurtz, J.E., additional, Guillemet, C., additional, Bompas, E., additional, Collard, O., additional, Salas, S., additional, Le Cesne, A., additional, Orbach, D., additional, Thery, J., additional, Deley, M-C. Le, additional, Mir, O., additional, and Penel, N., additional

Published
2021
Full Text
View/download PDF

46. 1523MO Initial active surveillance strategy for patients with peripheral sporadic desmoids: A multicentre phase II observational trial

Author

Bonvalot, S., primary, Lam, L., additional, Le Cesne, A., additional, Penel, N., additional, Blay, J-Y., additional, Michot, A., additional, Chevreau, C.M., additional, Anract, P., additional, Waast, D., additional, Piperno-Neumann, S., additional, Duffaud, F., additional, Malekzadeh, K., additional, Honoré, C., additional, Le Pechoux, C., additional, and Cozic, N., additional

Published
2021
Full Text
View/download PDF

47. 822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy

Author

Ray-Coquard, I.L., primary, Bompas, E., additional, Cropet, C., additional, Donnat, M., additional, Bertucci, F., additional, Chaigneau, L., additional, Metzger, S., additional, Dufresne, A., additional, Guillemet, C., additional, Pacaut Vassal, C., additional, Vénat-Bouvet, L., additional, Vegas, H., additional, Piperno-Neumann, S., additional, Fabbro, M., additional, Blay, J-Y., additional, Dubray-Longeras, P., additional, Savoye, A.M., additional, Brahmi, M., additional, and Floquet, A., additional

Published
2021
Full Text
View/download PDF

48. LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

Author

Pautier, P., primary, Italiano, A., additional, Piperno-Neumann, S., additional, Chevreau, C.M., additional, Penel, N., additional, Cupissol, D., additional, Boudou Rouquette, P., additional, Bertucci, F., additional, Balleyguier, C., additional, Lebrun-Ly, V., additional, Blay, J-Y., additional, Kalbacher, E., additional, Delcambre, C., additional, Bompas, E., additional, Collard, O., additional, Isambert, N., additional, Guillemet, C., additional, Rios, M., additional, Sundqvist, M., additional, and Duffaud, F., additional

Published
2021
Full Text
View/download PDF

49. LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

Author

Duffaud, F., primary, Chabaud, S., additional, Chevreau, C.M., additional, Italiano, A., additional, Perrin, C., additional, Isambert, N., additional, Piperno-Neumann, S., additional, Saada-Bouzid, E., additional, Bertucci, F., additional, Cupissol, D., additional, Kalbacher, E., additional, Narciso, B., additional, Schiffler, C., additional, de Sousa Carvalho, N., additional, Monard, L., additional, Bouvier, C., additional, Vidal, V., additional, Blay, J-Y., additional, and Mir, O., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results